Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KERENDIA vs DOCA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.
Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.
To reduce the risk of sustained e GFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes.
Adrenocortical insufficiency (Addison's disease),Salt-losing adrenogenital syndrome
10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.
Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.
The terminal elimination half-life is approximately 2–4 hours in healthy subjects. In patients with renal impairment, the half-life may be prolonged up to 6–8 hours, allowing for once-daily dosing in chronic kidney disease.
30-35 minutes; clinical context: short duration necessitates frequent dosing or continuous infusion for sustained effect.
Primarily metabolized by CYP3A4 (≈90%) and to a lesser extent by CYP2C8 (≈10%). No active metabolites.
Primarily hepatic metabolism via reduction and conjugation; little is known about specific CYP enzymes.
Approximately 80% of the dose is eliminated via feces (primarily as unchanged drug) and ~20% via urine (mostly as metabolites). Renal excretion of unchanged drug is minimal (less than 1%).
Primarily renal as metabolites; <5% unchanged. Biliary/fecal elimination is negligible (<2%).
Approximately 92% bound to plasma proteins, primarily albumin and alpha-1 acid glycoprotein.
~70% bound to plasma proteins (primarily albumin).
The apparent volume of distribution is approximately 50 L (about 0.7 L/kg in a 70 kg adult), indicating moderate tissue distribution, likely into kidney and heart tissues.
Vd: 0.8-1.2 L/kg; indicates extensive tissue distribution with rapid redistribution from effect sites.
Oral bioavailability is about 90–95% in healthy subjects, indicating nearly complete absorption after oral administration. Food does not significantly affect absorption.
Oral: <5% due to extensive first-pass metabolism; IM/SC: 100%.
e GFR 25-59 m L/min/1.73 m²: Initiate 10 mg once daily; continue 10 mg if tolerated. e GFR <25 m L/min: Not recommended.
No specific dose adjustment is recommended for impaired renal function, but monitor for fluid retention and hypertension. Use with caution in patients with significant renal impairment.
Child-Pugh B (moderate impairment): 10 mg once daily. Child-Pugh C (severe impairment): Not recommended.
No specific dose adjustment for hepatic impairment, but use with caution due to potential electrolyte disturbances.
Safety and efficacy not established in pediatric patients.
Dose is not well established; use 0.1 to 0.2 mg/kg intramuscularly daily or adjust based on clinical response and serum electrolytes.
No specific dose adjustment required; monitor renal function closely.
Start at the lower end of the dosing range (e.g., 1 to 2 mg IM daily) and monitor closely for fluid overload, hypertension, and electrolyte imbalances due to age-related decreased renal function and comorbidities.
No FDA boxed warning.
None
Hyperkalemia: Monitor serum potassium levels; may require dose adjustment or discontinuation.,Hypotension: Risk increased in patients with volume depletion or concomitant antihypertensive therapy.,Acute kidney injury: Monitor renal function; consider temporary discontinuation in setting of significant renal impairment.,Hepatic impairment: Not recommended in patients with severe hepatic impairment (Child-Pugh C).
Fluid overload and edema,Hypokalemia,Hypertension,Cardiac hypertrophy and failure,Increased risk of infection due to immune suppression when used with glucocorticoids
Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin, ketoconazole, ritonavir).,Addison's disease (adrenal insufficiency).,Serum potassium > 5.0 m Eq/L at initiation.
Hypersensitivity to desoxycorticosterone or any component,Severe renal impairment,Hyperkalemia,Hypocalcemia,Congestive heart failure,Systemic fungal infections
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 and may increase finerenone exposure. No other food interactions noted.
No specific food interactions are reported. However, maintain consistent sodium intake; do not restrict salt unless advised. Avoid potassium-rich foods if potassium levels are high. Alcohol may increase the risk of electrolyte disturbances.
Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiovascular, skeletal) were observed at maternal exposures below the maximum recommended human dose. In rabbits, increased post-implantation loss and decreased fetal weights occurred. There are no adequate human studies. Use is contraindicated in pregnancy. Avoid in women of childbearing potential not using effective contraception.
FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: risk of virilization of female fetuses; no adequate human studies; avoid use unless potential benefit outweighs risk.
No data on presence in human milk, effects on breastfed infant, or milk production. Excreted in rat milk. M/P ratio unknown. Due to potential for serious adverse reactions (e.g., hyperkalemia, hypotension), breastfeeding is not recommended during therapy and for 1 week after last dose.
Excreted in breast milk in low amounts; M/P ratio not established. Potential for adverse effects in nursing infants (e.g., electrolyte disturbances, hypertension). Use caution; consider alternative therapies.
Kerendia is contraindicated in pregnancy. No dose adjustments are provided due to lack of human data; use is not recommended. Pharmacokinetic changes in pregnancy are unknown, but dose modifications are not applicable as therapy should be discontinued if pregnancy occurs.
No specific dose adjustments studied; monitor for increased volume of distribution and clearance; adjust based on clinical response and serum electrolyte levels. Use lowest effective dose.
Monitor serum potassium closely, especially in patients with e GFR <30 m L/min/1.73m² or baseline K+ >5.0 m Eq/L. Avoid use with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir). Contraindicated with concomitant mineralocorticoid receptor antagonists (e.g., spironolactone, eplerenone). Use caution with moderate CYP3A4 inhibitors (e.g., erythromycin, verapamil) and moderate CYP3A4 inducers (e.g., rifampin, phenytoin). Assess e GFR and serum potassium before initiation and at 1 month after starting or adjusting dose.
DOCA (desoxycorticosterone acetate) is a mineralocorticoid used in adrenal insufficiency. Monitor serum potassium closely due to risk of hypokalemia from excessive mineralocorticoid activity. DOCA requires intramuscular injection; do not administer intravenously. Use in conjunction with glucocorticoids to mimic cortisol's permissive effects on catecholamines. Avoid in patients with hypertension, heart failure, or renal impairment due to sodium and water retention.
Take this medication exactly as prescribed, usually once daily with or without food.,Do not use potassium supplements or salt substitutes containing potassium without consulting your doctor.,Report symptoms of hyperkalemia (e.g., muscle weakness, fatigue, palpitations, numbness) immediately.,Avoid grapefruit and grapefruit juice during treatment.,Inform all healthcare providers that you are taking KERENDIA (finerenone).,Do not stop taking KERENDIA without talking to your doctor.,Store at room temperature, away from moisture and heat.
This medication helps maintain salt and water balance in the body.,It is given as an injection into a muscle; do not inject into a vein.,Report signs of excessive fluid retention: swelling in legs, rapid weight gain, shortness of breath.,Monitor for muscle cramps or weakness which may indicate low potassium levels.,Avoid salt substitutes containing potassium without consulting your doctor.,Do not miss appointments for injections as consistent dosing is critical.,Carry medical identification indicating you take corticosteroid replacement therapy.
No interactions on record
"Lidocaine, a sodium channel blocker and Class IB antiarrhythmic, inhibits hepatic CYP3A4, the primary enzyme responsible for the metabolism of quazepam, a benzodiazepine sedative-hypnotic. This inhibition reduces quazepam clearance, leading to elevated serum concentrations and enhanced sedative effects. Clinically, this may result in excessive sedation, respiratory depression, psychomotor impairment, and increased risk of falls, especially in elderly patients or those with hepatic impairment."
"Lidocaine and prilocaine are both amide-type local anesthetics that block voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse propagation. When used together, their systemic absorption can lead to additive cardiovascular and central nervous system toxicity, including arrhythmias, seizures, and methemoglobinemia, particularly with high doses or in patients with predisposing conditions."
"Lidocaine, a class Ib antiarrhythmic, inhibits CYP3A4, the primary enzyme responsible for the metabolism of ticagrelor, a P2Y12 platelet inhibitor. This inhibition can lead to increased plasma concentrations of ticagrelor, potentiating its antiplatelet effect and elevating the risk of major bleeding, such as gastrointestinal or intracranial hemorrhage. Conversely, reduced ticagrelor metabolism may also affect conversion to its active metabolite, though net effect still increases overall antiplatelet activity."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KERENDIA vs DOCA, answered by our medical review team.
KERENDIA is a Mineralocorticoid Receptor Antagonist that works by Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It binds to the MR and inhibits the recruitment of coactivators, thereby reducing the expression of pro-inflammatory and pro-fibrotic mediators in the kidney and heart.. DOCA is a Mineralocorticoid that works by Desoxycorticosterone acetate (DOCA) is a mineralocorticoid hormone that binds to mineralocorticoid receptors in the distal renal tubules, promoting sodium reabsorption and potassium excretion, leading to increased extracellular fluid volume and blood pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KERENDIA and DOCA depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KERENDIA is: 10 mg orally once daily initially, then titrate to 20 mg once daily after 4 weeks if tolerated.. The standard adult dose of DOCA is: Desoxycorticosterone acetate (DOCA) is administered intramuscularly at a dose of 2 to 5 mg daily or 10 mg every 12 hours initially, then reduced to 1 to 2 mg daily or every other day for maintenance. Alternatively, a pellet implant of 125 mg or 250 mg can be used for prolonged effect.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KERENDIA and DOCA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KERENDIA is classified as Category C. Based on animal studies, Kerendia (finerenone) is associated with fetal harm. In rats, embryofetal toxicity (reduced fetal weights, delayed ossification) and malformations (cardiov. DOCA is classified as Category C. FDA Pregnancy Category C. First trimester: feminization of male fetuses, including hypospadias and clitoral hypertrophy, due to androgenic activity. Second and third trimesters: ri. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.